Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Ofgem plans for standing charge reforms come under fire

(Sharecast News) - Plans by the UK's energy regulator to reform standing charges on consumer bills came under fire on Wednesday amid charges that the changes didn't go far enough or protect vulnerable customers. Ofgem said it wants suppliers to offer at least one tariff with lower standing charges. The daily controversial fee is levied on all customers whether they use energy gas and electricity or not.

However, campaigners said the new rules would make no difference to household bills as energy providers would just ramp up unit costs to recoup the cash.

Consumer affairs campaigner Martin Lewis called the proposals "disappointing". "The core problem is it doesn't look like it'll be under the price cap mechanism. That leads to two big possible problems," he told ITV on Wednesday.

Gillian Cooper, director of energy at Citizens Advice said: "Plans to offer a lower standing charge - the fixed cost of being connected to the electricity supply - may provide more choice to consumers but won't bring down people's bills."

"There's a real risk that those with higher energy needs, like some older or disabled people, could end up paying more if they choose one of these tariffs, so it's crucial people are supported to make the right choice when this option becomes more widely available from January."

Ofgem said it would start one final consultation on the plans and aimed to make a decision by the end of the year, meaning the new tariffs could be available by the end of January. .

The proposals come ahead of a two per cent rise in energy costs when the next price cap change takes effect on 1 October, which will see the bill for a typical household rise from £1,720 to £1,755 a year.

Reporting by Frank Prenesti for Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.